"The Economic Report" to Feature Kane Biotech Inc.

DEERFIELD BEACH, FLORIDA, Sep 02 (MARKET WIRE) --
The producers of The Economic Report, are pleased to announce that Kane
Biotech Inc. (TSX VENTURE: KNE) will be featured in an upcoming episode
on Emerging Developments in Biofilm Technologies as part of the show's
Medical Minutes series. This episode will air nationally on Fox Business
News and regionally on both CNN & Regional News Networks.

Scientists are finding that one of the ways microbes make us sick is by
arranging themselves in very sophisticated communities called biofilms.
Bacteria in biofilms like to stick together to everything from our teeth
to surgically implanted medical devices. Up to 80 percent of human
bacterial infections may involve biofilms and the cost of treating them
reaches billions of dollars a year in the United States alone. The
problem is that once they have formed, bacteria in biofilms become
extremely difficult to treat.

"Once in a biofilm, bacteria can be several orders of magnitude more
resistant to antibiotics than their planktonic (free-floating)
counterparts," says Dr. Srinivasa Madhyashta, Chief Scientific Officer
for Kane Biotech Inc. "Whatever the mechanism of drug resistance,
bacteria in biofilms often outlive treatment. A method of long-term
prevention of biofilm formation that acts at the level of the bioflim
formation is needed."

Kane Biotech is a leader in research and development of technologies and
products that prevent and remove bacterial biofilms. Its growing
portfolio is based upon leading research and relationships with prominent
academic institutions. The company is developing products that address
human health issues, including hospital acquired infections related to
medical devices, chronic wound healing and novel treatments in the
prevention of tooth decay.

The five-minute segment will be filmed on location at the Center for
Biofilm Engineering at Montana State University. It will include
interviews with the Center's director as well as officials from Kane
Biotech Inc.

To learn more about Kane Biotech, please visit www.kanebiotech.com and
for more information on the Center for Biofilm Engineering, please visit
www.erc.montana.edu/.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable Canadian
provincial securities legislation (collectively, "forward-looking
statements"). These forward-looking statements relate to, among other
things, our objectives, goals, targets, strategies, intentions, plans,
beliefs, estimates and outlook, including, without limitation, our
anticipated future operating results, and can, in some cases, be
identified by the use of words such as "believe," "anticipate," "expect,"
"intend," "plan," "will," "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.

These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors
or assumptions are applied in making forward-looking statements, and
actual results may differ materially from those expressed or implied in
such statements. Important factors that could cause actual results to
differ materially from these expectations include, among other things:
Kane's early stage of development, lack of product revenues and history
of operating losses, uncertainties related to clinical trials and product
development, rapid technological change, uncertainties related to
forecasts, competition, potential product liability, additional financing
requirements and access to capital, unproven markets, supply of raw
materials, income tax matters, management of growth, partnerships for
development and commercialization of technology, effects of insurers'
willingness to pay for products, system failures, dependence on key
personnel, foreign currency risk, risks related to regulatory matters and
risks related to intellectual property and other risks detailed from time
to time in Kane's filings with Canadian securities regulatory
authorities, as well as Kane's ability to anticipate and manage the risks
associated with the foregoing. Kane cautions that the foregoing list of
important factors that may affect future results is not exhaustive. When
relying on Kane's forward-looking statements to make decisions with
respect to Kane, investors and others should carefully consider the
foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management believes
to be reasonable assumptions, Kane cannot provide assurance that actual
results will be consistent with these forward-looking statements. Kane
undertakes no obligation to update or revise any forward-looking
statement.

The TSX Venture Exchange does not accept responsibility
for the adequacy or accuracy of this release.

Contacts:
Kane Biotech Inc.
Gord Froehlich
President and CEO
(204) 477-7592
(204) 453-1301 (FAX)
Email: gfroehlich@kanebiotech.com
Website: www.kanebiotech.com

Copyright 2008, Market Wire, All rights reserved.

-0-